Status:
WITHDRAWN
Early Detection of Heart Problems in Cancer Patients Receiving Chemotherapy
Lead Sponsor:
The Guthrie Clinic
Conditions:
Heart Failure
Eligibility:
All Genders
18+ years
Brief Summary
Subjects will include patients diagnosed with breast cancer or hematological cancer who are planned for chemotherapy treatment with anthracycline or trastuzumab; and who have one or more risk factors ...
Detailed Description
* Patients scheduled for potentially cardiotoxic chemotherapy would receive a baseline echocardiogram as per standard protocol which should be covered by the routine insurance * Follow-up with an extr...
Eligibility Criteria
Inclusion
- Males and females 18 years and above
- Willing and able to provide consent
- Able to read
- Patients diagnosed with breast cancer or hematological cancer who are planned for chemotherapy treatment with anthracycline or trastuzumab.
- Patients at increased risk of cardiotoxicity with one or more risk factors for heart disease:
- LVEF 50-54% by baseline echocardiogram
- Age ≥ 65
- BMI ≥ 30 kg/m2
- Current or prior anti-hypertensive therapy
- Diagnosis of coronary artery disease (CAD)
- Diabetes Mellitus
- Atrial fibrillation/flutter
Exclusion
- Children
- Patients who are pregnant
- Only single encounter without follow up
- Cancer diagnosis other than breast or hematological cancer
- Chemotherapy treatment other than anthracycline or trastuzumab
- No prior chemotherapy treatment
Key Trial Info
Start Date :
March 1 2020
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
May 28 2020
Estimated Enrollment :
Patients enrolled
Trial Details
Trial ID
NCT04413487
Start Date
March 1 2020
End Date
May 28 2020
Last Update
June 4 2020
Active Locations (0)
Enter a location and click search to find clinical trials sorted by distance.
No Results Found
We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.